Aptamer Group plc announces that it has developed a new reagent, Optimer®-Fc, for use in automated immunohistochemistry (IHC) workflows.

OGT announces that IVDR certification has been granted for eight CytoCell® fluorescence in situ hybridization (FISH) probes important for patient management in hematological cancers and prenatal conditions.

Personalis, Inc. has announced it will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.

Co-funded by Innovate UK, Aseptika is collaborating with the University of Birmingham, University of York and the National Audit of Cardiac Rehabilitation to study the impact of a hybrid delivery of cardiac rehabilitation.

Beckman Coulter Diagnostics and MeMed have announced a strategic partnership to jointly develop and commercialize a host immune response diagnostic that is able to distinguish between bacterial and viral infections for use on the Access Family of Immunoassay Analysers.

Abingdon Health plc announces the signing of a new distribution agreement with Salignostics for the launch of the first saliva-based pregnancy test in the UK and Ireland.

Owlstone Medical has announced the publication of a peer-reviewed study that identifies a set of volatile organic compounds that can identify patients with liver disease and separate them based on severity.

MIP Discovery has announced it has secured a significant grant of funds from the Bill & Melinda Gates Foundation.

Beckman Coulter Life Sciences further strengthens its commitment to the greater Loveland, Colorado community with the completion of the first phase of its new research and development hub.

Isohelix (UK) announces that it has commenced engagement with the U.S. Food and Drug Administration to progress the full regulatory approval of the GeneFix® Saliva DNA Collectors into the USA.